The global Macular Degeneration Drug Pipeline market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Macular Degeneration Drug Pipeline, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration Drug Pipeline.
Report Scope
The Macular Degeneration Drug Pipeline market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Macular Degeneration Drug Pipeline market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Macular Degeneration Drug Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Amgen
Roche
Adverum Biotechnologies
AsclepiX Therapeutics
Bioeq AG
Sinocelltech
RemeGen
Grifols, S.A.
Kyowa Kirin
EyePoint Pharmaceutical
IVERIC Bio
Kodiak Sciences
Ribomic
Lineage Cell Therapeutics
Graybug Vision
CHABiotech
Shanghai Henlius Biotech
Bio-Thera Solutions
Alteogen
Outlook Therapeutics
Segment by Type
Gene therapy
Small molecules
Stem cell therapy
Gene therapies
Segment by Application
Hospital
Research Institute
Commercial
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Macular Degeneration Drug Pipeline companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Macular Degeneration Drug Pipeline 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gene therapy
1.2.3 Small molecules
1.2.4 Stem cell therapy
1.2.5 Gene therapies
1.3 麻豆原创 by Application
1.3.1 Global Macular Degeneration Drug Pipeline 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Commercial
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Macular Degeneration Drug Pipeline 麻豆原创 Perspective (2019-2030)
2.2 Macular Degeneration Drug Pipeline Growth Trends by Region
2.2.1 Global Macular Degeneration Drug Pipeline 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Macular Degeneration Drug Pipeline Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Macular Degeneration Drug Pipeline Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Macular Degeneration Drug Pipeline 麻豆原创 Dynamics
2.3.1 Macular Degeneration Drug Pipeline Industry Trends
2.3.2 Macular Degeneration Drug Pipeline 麻豆原创 Drivers
2.3.3 Macular Degeneration Drug Pipeline 麻豆原创 Challenges
2.3.4 Macular Degeneration Drug Pipeline 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue
3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2019-2024)
3.1.2 Global Macular Degeneration Drug Pipeline Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Macular Degeneration Drug Pipeline 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue
3.4 Global Macular Degeneration Drug Pipeline 麻豆原创 Concentration Ratio
3.4.1 Global Macular Degeneration Drug Pipeline 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2023
3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served
3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service
3.7 Date of Enter into Macular Degeneration Drug Pipeline 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Macular Degeneration Drug Pipeline Breakdown Data by Type
4.1 Global Macular Degeneration Drug Pipeline Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Macular Degeneration Drug Pipeline Forecasted 麻豆原创 Size by Type (2025-2030)
5 Macular Degeneration Drug Pipeline Breakdown Data by Application
5.1 Global Macular Degeneration Drug Pipeline Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Macular Degeneration Drug Pipeline Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Macular Degeneration Drug Pipeline 麻豆原创 Size (2019-2030)
6.2 North America Macular Degeneration Drug Pipeline 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2019-2024)
6.4 North America Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Macular Degeneration Drug Pipeline 麻豆原创 Size (2019-2030)
7.2 Europe Macular Degeneration Drug Pipeline 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2019-2024)
7.4 Europe Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Macular Degeneration Drug Pipeline 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Macular Degeneration Drug Pipeline 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Macular Degeneration Drug Pipeline 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Macular Degeneration Drug Pipeline 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Macular Degeneration Drug Pipeline 麻豆原创 Size (2019-2030)
9.2 Latin America Macular Degeneration Drug Pipeline 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Macular Degeneration Drug Pipeline 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Macular Degeneration Drug Pipeline 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Macular Degeneration Drug Pipeline 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.1.5 Amgen Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Adverum Biotechnologies
11.3.1 Adverum Biotechnologies Company Detail
11.3.2 Adverum Biotechnologies Business Overview
11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.3.5 Adverum Biotechnologies Recent Development
11.4 AsclepiX Therapeutics
11.4.1 AsclepiX Therapeutics Company Detail
11.4.2 AsclepiX Therapeutics Business Overview
11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.4.5 AsclepiX Therapeutics Recent Development
11.5 Bioeq AG
11.5.1 Bioeq AG Company Detail
11.5.2 Bioeq AG Business Overview
11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.5.5 Bioeq AG Recent Development
11.6 Sinocelltech
11.6.1 Sinocelltech Company Detail
11.6.2 Sinocelltech Business Overview
11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.6.5 Sinocelltech Recent Development
11.7 RemeGen
11.7.1 RemeGen Company Detail
11.7.2 RemeGen Business Overview
11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.7.5 RemeGen Recent Development
11.8 Grifols, S.A.
11.8.1 Grifols, S.A. Company Detail
11.8.2 Grifols, S.A. Business Overview
11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.8.5 Grifols, S.A. Recent Development
11.9 Kyowa Kirin
11.9.1 Kyowa Kirin Company Detail
11.9.2 Kyowa Kirin Business Overview
11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.9.5 Kyowa Kirin Recent Development
11.10 EyePoint Pharmaceutical
11.10.1 EyePoint Pharmaceutical Company Detail
11.10.2 EyePoint Pharmaceutical Business Overview
11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.10.5 EyePoint Pharmaceutical Recent Development
11.11 IVERIC Bio
11.11.1 IVERIC Bio Company Detail
11.11.2 IVERIC Bio Business Overview
11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.11.5 IVERIC Bio Recent Development
11.12 Kodiak Sciences
11.12.1 Kodiak Sciences Company Detail
11.12.2 Kodiak Sciences Business Overview
11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.12.5 Kodiak Sciences Recent Development
11.13 Ribomic
11.13.1 Ribomic Company Detail
11.13.2 Ribomic Business Overview
11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.13.5 Ribomic Recent Development
11.14 Lineage Cell Therapeutics
11.14.1 Lineage Cell Therapeutics Company Detail
11.14.2 Lineage Cell Therapeutics Business Overview
11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.14.5 Lineage Cell Therapeutics Recent Development
11.15 Graybug Vision
11.15.1 Graybug Vision Company Detail
11.15.2 Graybug Vision Business Overview
11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.15.5 Graybug Vision Recent Development
11.16 CHABiotech
11.16.1 CHABiotech Company Detail
11.16.2 CHABiotech Business Overview
11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.16.5 CHABiotech Recent Development
11.17 Shanghai Henlius Biotech
11.17.1 Shanghai Henlius Biotech Company Detail
11.17.2 Shanghai Henlius Biotech Business Overview
11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.17.5 Shanghai Henlius Biotech Recent Development
11.18 Bio-Thera Solutions
11.18.1 Bio-Thera Solutions Company Detail
11.18.2 Bio-Thera Solutions Business Overview
11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.18.5 Bio-Thera Solutions Recent Development
11.19 Alteogen
11.19.1 Alteogen Company Detail
11.19.2 Alteogen Business Overview
11.19.3 Alteogen Macular Degeneration Drug Pipeline Introduction
11.19.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.19.5 Alteogen Recent Development
11.20 Outlook Therapeutics
11.20.1 Outlook Therapeutics Company Detail
11.20.2 Outlook Therapeutics Business Overview
11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction
11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2019-2024)
11.20.5 Outlook Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Amgen
Roche
Adverum Biotechnologies
AsclepiX Therapeutics
Bioeq AG
Sinocelltech
RemeGen
Grifols, S.A.
Kyowa Kirin
EyePoint Pharmaceutical
IVERIC Bio
Kodiak Sciences
Ribomic
Lineage Cell Therapeutics
Graybug Vision
CHABiotech
Shanghai Henlius Biotech
Bio-Thera Solutions
Alteogen
Outlook Therapeutics
听
听
*If Applicable.
